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Available online 11 March 2018Background: Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine are
established predictors of total and cardiovascular mortality. However, the predictive capacity of ADMA and
SDMA for hospital and 3-months mortality of patients with acute heart failure (AHF) is unknown.
Methods& results:Out of 152 includedAHFpatients, 79 (52%)were female, and themean patient agewas 75.2±
10.3 years. Hospital and three-month mortality rates were 14.5% and 27.4%, respectively. Serum ADMA and
SDMA levels at admission, determined by reversed phase high performance liquid chromatography, were higher
in patients having at least one of the three signs implying venous volume overload (enlarged liver, ascites, pe-
ripheral edema), a consequence of right-sided heart failure, compared to patients without those signs.
Univariable logistic regression analyses revealed a signiﬁcant positive association of ADMA and SDMAconcentra-
tions with hospital mortality [odds ratio (OR) and 95% conﬁdence interval (CI) per standard deviation (SD) in-
crease: 2.22 (1.37–3.79), p = 0.002, and 2.04 (1.34–3.18), p = 0.001, respectively], and 3-months mortality
[2.06 (1.36–3.26), p= 0.001, and 2.52 (1.67–4.04), p b 0.001, respectively]. These associations remained signif-
icant after adjusting for age, sex,mean arterial pressure, low-density lipoprotein cholesterol, glomerularﬁltration
rate, and N-terminal pro-brain natriuretic peptide.
Conclusions:We conclude that ADMA and SDMA concentrations are associated with hospital and 3-month mor-
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Mortality1. Introduction
Despite achievements in prevention, diagnosis and treatment, heart
failure (HF) is still a frequent cause of death and disability worldwide
[1]. HF is deﬁned by the European Society of Cardiology (ESC) as anADMA, asymmetric
ic oxide; NT-proBNP,
ion rate; MAP, mean
y lipoprotein; NYHA,
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of Cardiology; eNOS,
r for Cell Signaling,
cal University of Graz,
n open access article underabnormality of cardiac structure and function, resulting in failure of
the heart to deliver oxygen at a rate commensurate with the require-
ments of the metabolizing tissues [2,3]. Acute heart failure (AHF) de-
notes the rapid onset of, or changes in, symptoms and signs of HF [3].
Accurate prognostic biomarkers are crucial for risk assessment, timely
and appropriate therapeutic interventions and the overall management
of AHF.
Asymmetric dimethylarginine (ADMA) and symmetric
dimethylarginine (SDMA) are products of intracellular proteolysis of
proteins containing methylated arginines [4]. Serum concentrations of
ADMA and SDMA are determined by the rate of their release from the
cells, tissue degradation and the rate of renal elimination [4]. Both
ADMA and SDMA exert a negative effect on vascular nitric oxide (NO)
bioavailability [5], implicating their role in the cardiovascular patho-
physiology related to endothelial dysfunction [6,7]. In line with this,
both ADMA and SDMA have been found to independently predict totalthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Laboratory parameters and MAP in patients with or without sign(s) implying volume
overload.
No sign
(N = 42)
Sign(s)
(N = 110)
p-Value
ADMA (μmol/L) 0.7 (0.5–1.2) 0.9 (0.5–1.4) 0.001
SDMA (μmol/L) 1.1 (0.5–2.6) 1.5 (0.5–4.3) 0.002
GFR (ml/min/1.73 m2) 50.6 (19.6–105.7) 51.0 (15.0–104.8) 0.517
Urea (mmol/L) 8.0 (3.0–64.0) 8.0 (3.0–41.0) 0.063
Creatinine (μmol/L) 48.0 (18.6–138.0) 47.0 (6.0–151.0) 0.534
NT-proBNP (ng/mL) 8.3 (0.7–70.0) 9.6 (0.2–70.0) 0.214
ALT (U/L) 23.0 (7.0–145.0) 23.0 (6.0–623.0) 0.610
AST (U/L) 24.0 (14.0–369.0) 28.0 (10.0–666.0) 0.843
IL-6 (pg/mL) 19.2 (0.4–300.0) 21.4 (1.2–300.0) 0.968
CRP (μg/mL) 4.5 (0.2–71.6) 11.5 (0.5–247.4) 0.004
Protein (g/L) 71.5 (36.0–87.0) 66.0 (31.0–86.0) b0.001
Fibrinogen (g/L) 3.8 (2.4–12.1) 3.5 (1.1–9.4) 0.003
Albumin (g/L) 39.5 (24.0–72.0) 40.0 (21.0–62.0) 0.580
Total cholesterol (mmol/L) 4.5 (2.5–9.1) 3.8 (1.7–8.5) 0.001
LDL-cholesterol (mmol/L) 2.7 (1.3–6.3) 2.2 (0.8–6.1) 0.004
HDL-cholesterol (mmol/L) 1.1 (0.4–2.3) 0.9 (0.3–3.6) 0.027
Triglycerides (mmol/L) 1.2 (0.6–4.3) 1.0 (0.5–3.2) 0.002
MAP (mm Hg) 109.2 (65.0–158.3) 100.0 (53.3–160.0) 0.034
Data are presented as median and range (minimum to maximum). Differences between
patients without any sign and those with at least one of the three signs implying venous
volume overload (enlarged liver, peripheral edema, ascites) were tested with the
Mann-Whitney U test; signiﬁcant differences are depicted in bold.
ADMA, asymmetric dimethylarginine; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; BMI, body mass index; CRP, C-reactive protein; GFR, glomerular
ﬁltration rate; IL-6, interleukin-6; LDL, low-density lipoprotein; HDL, high-density
lipoprotein; MAP, mean arterial pressure; NT-proBNP, N-terminal pro brain natriuretic
peptide; SDMA, symmetric dimethylarginine.
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ADMA levels are predictive for disease progression and adverse long-
term outcomes in chronic systolic HF patients [11].
2. Theory
Since it is known that ADMA and SDMA are associated with the car-
diovascular pathophysiology as well as mortality, but the association
with AHF mortality has not yet been studied, the aim of the present
study was therefore to examine the predictive capacity of ADMA and
SDMA for hospital and 3-months mortality in AHF patients.
3. Methods
3.1. Study design and patients
Wepreviously reported on study design, inclusion and exclusion criteria aswell as pa-
tient characteristics for our AHF cohort [12,13]. Written informed consent was obtained
from each patient and the study was conducted in adherence to the ethical guidelines of
the Declaration of Helsinki [14], as reﬂected in a priori approval by the Ethics Committees
of the University Hospital Centre Sisters of Charity, Zagreb, Croatia and the Medical
University of Graz, Austria. All patients were treated according to the ESC Guidelines for
AHF [3,15].
3.2. Laboratory procedures
The collection of blood samples, standard laboratorymethods, and the determination
of the N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) concentration were de-
scribed in our previous reports on our AHF cohort [13,16]. ADMA and SDMA levels were
determined according to our previouswork [8,9]. The concentration of ﬁbrinogenwas de-
termined with a blood coagulometer (BCS XP, Siemens, Germany). The levels of alanine
aminotransferase (ALT) and aspartate aminotransferase (AST) were determined with
Architect c8000, Abbott 2013 (Chicago, IL, USA).
3.3. Statistical analyses
Categorical data are shown as absolute and relative frequencies, whereas continuous
data are summarized as median and range (minimum to maximum) due to the skewed
distribution of many of the laboratory parameters. Patients with and without signs of ve-
nous volume overloadwere compared by theMann-WhitneyU test and Fisher's exact test.
Correlations between ADMA, SDMA and various laboratory and clinical parameters were
determinedby the Spearman correlation coefﬁcient. Univariable andmultivariable logistic
regression analyses were used to examine the impact of ADMA and SDMA levels on
hospital and 3-month mortality. In the multivariable analyses, we adjusted for age, sex,
NT-proBNP, GFR, mean arterial pressure (MAP) as well as low-density lipoprotein (LDL)
cholesterol and checked the variance inﬂation factor to prevent multi-collinearity
among the covariates. Results are presented as odds ratio (OR) and the respective 95%
conﬁdence interval (CI) per standard deviation (SD) increase. Presentation on the SD
scale is warranted because ADMA and SDMA values were normally distributed. R version
3.4.2 was used for all statistical analyses.
4. Results
4.1. Patients' clinical characteristics and laboratory parameters
The patients' baseline characteristics have been described elsewhere
[12]. Out of 152 included patients, 79 (52%) were female and the mean
(SD) age was 75.2 ± 10.3 years. According to the New York Heart
Association Functional Classiﬁcation (NYHA), 11 (7.2%) patients
belonged to class 2, 83 (54.6%) to class 3, and 58 (38.2%) to class 4. Fre-
quent comorbidities were hypertension (89.5%), type 2 diabetes
mellitus (51.7%), hyperlipidemia/hypertriglyceridemia (39.5%), and hy-
percholesterolemia (38.8%). Regarding previousmedication 41 (27%) of
patients were treated with statins, 67 (45%) with β-blockers, 86 (57%)
with angiotensin-converting enzyme inhibitors (ACEI), and 25 (16.6%)
with amlodipine. Worsening of chronic HF occurred in 105 (69.1%) pa-
tients and 61 (42.4%) had a preserved ejection fraction. Regarding signs
at admission reﬂecting venous volume overload as a consequence of
right-sided HF, 53 (34.9%) patients had an enlarged liver, 21 (13.8%)
had ascites, and 105 (69.1%) had a peripheral edema (with possible
overlaps); 110 (72.4%) patients had at least one of the signs and
11 (7.2%) had all three. Median (range) length of hospitalization was
9 (0.0–85.0) days. Twenty-two (14.5%) patients died in the hospital;the number increased to 40 (27.4%) three months after admission. Me-
dian and range for ADMA and SDMA levels were 0.8 (0.5–1.4) μmol/L
and 1.4 (0.5–4.3), respectively; ﬁbrinogen concentration was 3.6
(1.1–12.1) g/L and the levels of ALT and AST were 23.0 (6.0–623.0) U/L
and 27.0 (10.0–666.0), respectively. Other laboratory parameters have
been reported previously [16].
4.2. Impact of venous volume overload on serum levels of laboratory
parameters and MAP
To examine whether venous volume overload, a consequence of
right-sided HF, affects serum levels of ADMA, SDMA, various laboratory
parameters, andMAP,we compared their levels in patients with at least
one of the three signs implying venous volume overload (enlarged liver,
ascites or peripheral edema) to those without. As shown in Table 1, the
concentrations of ADMA, SDMA, and CRP were signiﬁcantly higher in
patients with signs whereas the concentrations of total serum proteins,
ﬁbrinogen, total cholesterol, LDL cholesterol, HDL-cholesterol, triglycer-
ides, and MAP were signiﬁcantly decreased. The kidney function
markers, GFR, urea, and creatinine as well as serum albumin, a marker
for the biosynthetic capacity of the liver, and NT-proBNP, a marker for
HF severity, as well as ALT and AST were similar in patients with and
without signs.
4.3. Correlation of ADMA and SDMA concentrations with laboratory and
clinical parameters
As shown in Table 2 the concentrations of ADMA and SDMA were
positively correlated with patients' age and negatively with MAP, GFR
and ﬁbrinogen. SDMA, (but not ADMA), was further positively corre-
lated with urea, creatinine and NT-proBNP and negatively with the
serum protein concentration, as well as the total and HDL cholesterol
serum levels. No signiﬁcant correlation with either ADMA or SDMA
was observed for body mass index (BMI), interleukin-6 (IL-6),
C-reactive protein (CRP), AST, ALT, serum albumin, LDL cholesterol, tri-
glycerides, left ventricular ejection fraction (LVEF), and length of
Table 2
Correlation analyses of ADMA and SDMA concentrations with clinical and laboratory
parameters.
ADMA (μmol/L) SDMA (μmol/L)
r p-Value N r p-Value N
Age (years) 0.28 0.001 131 0.26 0.002 137
BMI (kg/m2) −0.10 0.250 131 −0.17 0.054 137
GFR (ml/min/1.73 m2) −0.20 0.021 130 −0.66 b0.001 136
Urea (mmol/L) 0.13 0.137 130 0.51 b0.001 136
Creatinine (mol/L) 0.07 0.397 130 0.56 b0.001 136
NT-proBNP (pg/mL) 0.15 0.094 126 0.50 b0.001 131
AST (U/L) −0.07 0.426 128 0.08 0.370 134
ALT (U/L) −0.15 0.096 127 −0.06 0.504 133
IL-6 (pg/mL) −0.01 0.876 131 0.17 0.053 137
CRP (μg/mL) 0.02 0.785 129 0.14 0.094 135
Protein (g/L) −0.11 0.227 129 −0.24 0.006 134
Fibrinogen (g/L) −0.25 0.005 126 −0.24 0.006 132
Albumin (g/L) −0.08 0.357 128 −0.13 0.121 134
Total cholesterol (mmol/L) −0.14 0.113 131 −0.25 0.003 137
LDL-cholesterol (mmol/L) −0.08 0.373 131 −0.16 0.068 137
HDL-cholesterol (mmol/L) −0.17 0.060 131 −0.22 0.009 137
Triglycerides (mmol/L) 0.01 0.919 131 −0.06 0.506 137
MAP (mm Hg) −0.21 0.016 131 −0.33 b0.001 137
LVEF (%) 0.05 0.549 122 −0.17 0.052 127
Length of hospitalization (days) −0.02 0.785 129 0.15 0.081 135
Data are presented as Spearman correlation coefﬁcient r, p-value, and number of available
samples; signiﬁcant correlations are depicted in bold.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index;
CRP, C-reactive protein; GFR, glomerular ﬁltration rate; HDL, high-density lipoprotein;
IL-6, interleukin 6; LDL, low-density lipoprotein; NT-proBNP, N-terminal pro brain
natriuretic peptide; SDMA, symmetric dimethylarginine.
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lated with each other (r= 0.47, p b 0.001).
4.4. Logistic regression analyses
The association of ADMA and SDMA with hospital and 3-month
mortality in AHF patients was examined by logistic regression analyses
(Table 3). The univariable analyses showed a signiﬁcant positive associ-
ation of both ADMA and SDMA levels with hospital and 3-month mor-
tality. Importantly, these associations remained signiﬁcant even after
adjusting for age, sex, NT-proBNP, GFR, MAP and LDL cholesterol, the
clinical and laboratory parameters that are known to be associated
with mortality in HF patients.
5. Discussion
It is well established that accurate prognostic biomarkers are crucial
for risk assessment, efﬁcient therapeutic intervention, and overall man-
agement of HF. Previous studies highlighted both ADMA and SDMA as
independent risk markers for total and cardiovascular mortality and
cardiovascular disease [8,10]. However, no study to date has examined
the association of ADMA and SDMA with mortality in AHF patients.Table 3
Univariable and multivariable logistic regression analyses of hospital and 3-month mortality fo
Unadjusted
OR (95% CI) p-Value Eve
Hospital mortality
ADMA (μmol/L) 2.22 (1.37–3.79) 0.002 20/
SDMA (μmol/L) 2.04 (1.34–3.18) 0.001 21/
3-month mortality
ADMA (μmol/L) 2.06 (1.36–3.26) 0.001 34/
SDMA (μmol/L) 2.52 (1.67–4.04) b0.001 37/
OR and CI are presented on the SD scale (increase per 1 SD); SDs for ADMA and SDMA are 0.1
a The model was adjusted for age, sex, NT-proBNP, GFR, MAP and LDL-cholesterol. ADMA, a
low-density lipoprotein; MAP, mean arterial pressure; NT-proBNP, N-terminal brain natriuretiThe present study shows, for the ﬁrst time, that high serum levels
of ADMA or SDMA are independently associated with both hospital
and 3-months mortality in AHF patients.
Furthermore, we show that ADMA and SDMA levels are increased
in patients with signs implying venous volume overload (enlarged
liver, peripheral edema, ascites), a consequence of right-sided HF.
Given that different pathophysiological states and medication affect
ADMA and SDMA serum levels, the baseline serum levels of these me-
tabolites in our AHF patients reﬂect not only the impact of the AHF path-
ophysiology, but also, at least in part, the impact of the associated
comorbidities and medication [5]. In the present study, comorbidities
and prior medication were neither associated with mortality nor
did they affect the association of ADMA and SDMA with mortality
(Supplementary Tables 1–3).
The crucial role of endothelium-derived NO in the maintenance of a
normal cardiac function and the inhibition of adverse ventricular re-
modeling is well established [17,18]. In line with this, it has been
shown that administration of NO improves the left ventricle diastolic
function in HF patients [19] and that chronic inhibition of the endoge-
nous NO production is associated with severe myocardial ﬁbrosis in an-
imal models [20]. Accordingly, the well-documented diminishing effect
of ADMA and SDMA on the vascular NO bioavailability, due to inhibition
of the endothelial nitric oxide synthase (eNOS) activity by ADMA and
the interference of SDMA with the utilization of the eNOS substrate
L-arginine [4,5], may well explain the link between ADMA, SDMA and
AHF mortality. Additionally, considering that HDL function, including
the activation of the eNOS/NO pathway [21], is attenuated by methyl-
ated arginine species [22], it is conceivable that ADMA and SDMA
exert deleterious effects through HDL dysfunction. Moreover, increased
ADMAand SDMA levels in AHFpatientswith signs implying venous vol-
ume overload, a condition associated with venous congestion as well as
hemodynamic and metabolic perturbations [23], suggest an association
of ADMA and SDMA with a more severe stage of AHF. This additionally
supports the association of ADMA and SDMA with mortality. Indeed,
an increase (albeit not statistically signiﬁcant) in hospital (16.4% vs.
9.5%, p = 0.439) and 3-month mortality (31.7% vs. 16.7%, p = 0.069)
was observed in patients with at least one sign, compared to patients
without.
In line with previous studies, we observed a strong association of
SDMA and a less profound association of ADMA with parameters indi-
cating renal function [24]. In contrast to the reported association of ve-
nous volume overload with impaired renal function [25], we did not
observe that the markers of kidney function (including GFR, urea and
creatinine), were altered by venous volume overload (Table 1). This
indicates that venous volume overload deﬁned by the presence of en-
larged liver, ascites or peripheral edema, was not accompanied by
renal congestion or that the degree of renal congestion was insufﬁcient
to affect renal function.
The negative association of SDMA, but not of ADMA,with serumpro-
teins, as well as total and HDL-cholesterol might be a consequence of a
positive association of SDMAwith the severity of HF, which is known tor ADMA and SDMA.
Adjusteda
nts/N OR (95% CI) p-Value Events/N
131 2.15 (1.17–4.29) 0.019 19/125
137 1.83 (1.01–3.39) 0.045 20/130
126 2.28 (1.38–3.98) 0.002 32/120
132 1.88 (1.14–3.28) 0.017 35/125
7 and 0.81 μmol/L, respectively.
symmetric dimethylarginine; CI, conﬁdence interval; GFR, glomerular ﬁltration rate; LDL,
c peptide; OR, odds ratio; SD, standard deviation; SDMA, symmetric dimethylarginine.
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dominance [23]. Indeed, SDMA, (but not ADMA) levels, were strongly
positively correlated with NT-proBNP, an established marker for the
severity of HF (Table 2).
It is conceivable that intestinal congestion, and thereby accompa-
nied intestinal edema, as well as an impaired nutrient absorption,
together with a diminished biosynthetic activity of the congested
liver, underlie the decreased circulating proteins and lipids in
our patients with venous volume overload. This would be in line with
a previous study suggesting that hepatic congestion, a consequence of
right-sided HF, rather than hypo-perfusion, causes liver dysfunction
[26].
Since in the present study ALT and AST levels were similar in pa-
tients with and without signs, it seems that venous volume overload
was not associated with any hepatocyte damage, but rather with an im-
paired hepatic biosynthetic activity.
Interestingly, in contrast to decreased levels of total serum proteins
and ﬁbrinogen, the levels of albumin, a marker for nutritional status
and the biosynthetic capacity of the liver, were not altered in patients
with signs (Table 1). Unaltered albumin levels probably reﬂect the con-
tribution of certain compensatingmechanisms, namely the net transfer
of extravascular albumin into the intravascular pool, and the decreased
albumin catabolic rate, which are both operative for albumin [27,28],
but not ﬁbrinogen [29], when biosynthetic capacity of the liver is
diminished.
Quite opposite to what was found for serum proteins and lipids, the
levels of ADMA and SDMA were increased in patients with at least one
sign implying volume overload. Several potential mechanisms may
explain this observation: First, increased ADMA and SDMA levels have
previously been observed in various pathophysiological conditions
associated with increased protein-turnover [30,31]. An increased rate
of protein-turnover, likely caused by limited delivery of nutrients due
to intestinal edema and impaired intestinal absorption, may in turn ex-
plain increased ADMA and SDMA levels in AHF patients with signs. Sec-
ond, itmight be that tissue congestion augments themethylation rate of
arginine residues in cellular proteins, or the release of ADMA and SDMA
into the circulation. Importantly, increased gene and protein expression
of the ADMA-degrading enzyme, dimethylaminohydrolases-1, was ob-
served in end-stage failing human hearts upon ventricular unloading
following the support with a left ventricular assist device [32]. This ﬁnd-
ing strongly supports the notion that the decreased expression and ac-
tivities of ADMA- and SDMA-degrading enzymes in the congested
tissuemight be responsible for increasedADMA and SDMA serum levels
when there is a venous volume overload, as observed in our patients
with signs. Accordingly, it is likely that the alleviation of congestion by
diuretics decreased ADMA and SDMA levels in our AHF patients upon
hospitalization. Furthermore, other pharmacological interventions,
such as angiotensin-converting enzyme inhibitors, angiotensin receptor
blockers, or some statins, are capable of decreasing ADMA levels [5] and
were used for treatment of our AHF patients. Therefore, it is conceivable
that either one or a combination of these pharmacological approaches
might have affected ADMA and SDMA levels and consequently the
effect thereof onmortality. However,medication on theﬁrst and second
day of hospitalization was neither associated with mortality nor
did it affect the association of ADMA and SDMA with mortality
(Supplementary Tables 4–7).
We found that ADMA and SDMA were not signiﬁcantly correlated
with IL-6 or CRP serum levels, but were negatively correlated with ﬁ-
brinogen (Table 2), an acute phase protein that was itself positively cor-
related with CRP (r = 0.33, p b 0.001) and IL-6 (r = 0.22, p = 0.007).
This suggests that in our AHF patients both ADMA and SDMA levels
were not affected by the patients' inﬂammatory status. Accordingly,
the negative correlations of both ADMA and SDMA with ﬁbrinogen
conceivably reﬂect that they are regulated into opposite directions by
venous volume overload, a state that was accompanied by increased
CRP levels in the present study (Table 1).5.1. Study limitations
There are several limitations to our present study: The design does
not allow us to draw conclusions about cause and effect for the patho-
physiological processes involved in the regulation of ADMA and SDMA
serum levels. Furthermore, we cannot provide a mechanistic explana-
tion on how ADMA and SDMA affect mortality. In addition, by deﬁning
venous volume overload solely as the presence of signs implying
volume overload, we were unable to test the impact of the extent
of volume overload, as would have been possible with data on the
right ventricle end diastolic diameter or the diameter of the right
atrium. Finally, the moderate number of participants (n= 152) in this
monocentric study inﬂuences the statistical power of our analyses.
Therefore, further large studies are needed to conﬁrm our results.
6. Conclusions
Based on our results, we conclude that serum concentrations of both
ADMA and SDMA are associated with hospital and 3-month mortality
and are increased by venous volume overload in AHF patients.
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